Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture – Pipeline Review, H1 2017, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.
Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
American Gene Technologies International Inc
Arcarios BV
AstraZeneca Plc
Biogenomics Ltd
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Kuros Biosciences AG
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Fracture – Overview
Bone Fracture – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture – Companies Involved in Therapeutics Development
American Gene Technologies International Inc
Arcarios BV
AstraZeneca Plc
Biogenomics Ltd
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Kuros Biosciences AG
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
Bone Fracture – Drug Profiles
ALLOB – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-2858 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-1221 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dibotermin alfa biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-436/9 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LWnt-3a – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Midkine for Bone Fractures – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OsteoStem – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rusalatide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-86 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Fracture Repair – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture – Dormant Projects
Bone Fracture – Discontinued Products
Bone Fracture – Product Development Milestones
Featured News & Press Releases
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting
Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture
Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture
Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial
Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bone Fracture, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Bone Fracture – Pipeline by American Gene Technologies International Inc, H1 2017
Bone Fracture – Pipeline by Arcarios BV, H1 2017
Bone Fracture – Pipeline by AstraZeneca Plc, H1 2017
Bone Fracture – Pipeline by Biogenomics Ltd, H1 2017
Bone Fracture – Pipeline by BiologicsMD Inc, H1 2017
Bone Fracture – Pipeline by Biopharm GmbH, H1 2017
Bone Fracture – Pipeline by Bone Therapeutics SA, H1 2017
Bone Fracture – Pipeline by Cellmid Ltd, H1 2017
Bone Fracture – Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
Bone Fracture – Pipeline by Entera Bio Ltd, H1 2017
Bone Fracture – Pipeline by Escape Therapeutics Inc, H1 2017
Bone Fracture – Pipeline by ethris GmbH, H1 2017
Bone Fracture – Pipeline by Kuros Biosciences AG, H1 2017
Bone Fracture – Pipeline by Novartis AG, H1 2017
Bone Fracture – Pipeline by Pluristem Therapeutics Inc, H1 2017
Bone Fracture – Pipeline by TissueGene Inc, H1 2017
Bone Fracture – Pipeline by Viking Therapeutics Inc, H1 2017
Bone Fracture – Dormant Projects, H1 2017
Bone Fracture – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Bone Fracture, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
